137 related articles for article (PubMed ID: 2824958)
21. Baroreflex-mediated bradycardia is blunted by intravenous mu- but not kappa-opioid agonists.
Omoniyi AT; Wu D; Soong Y; Szeto HH
J Cardiovasc Pharmacol; 1998 Jun; 31(6):954-9. PubMed ID: 9641482
[TBL] [Abstract][Full Text] [Related]
22. Central effects of mu, delta, and kappa receptor agonists in hemorrhagic shock.
Feuerstein G; Powell E; Faden AI
Peptides; 1985; 6 Suppl 1():11-3. PubMed ID: 2995939
[TBL] [Abstract][Full Text] [Related]
23. Immunomodulatory activity of mu- and kappa-selective opioid agonists.
Taub DD; Eisenstein TK; Geller EB; Adler MW; Rogers TJ
Proc Natl Acad Sci U S A; 1991 Jan; 88(2):360-4. PubMed ID: 1846441
[TBL] [Abstract][Full Text] [Related]
24. Opioid receptor subtypes in the supraoptic nucleus and posterior pituitary gland of morphine-tolerant rats.
Sumner BE; Coombes JE; Pumford KM; Russell JA
Neuroscience; 1990; 37(3):635-45. PubMed ID: 2174133
[TBL] [Abstract][Full Text] [Related]
25. Medial thalamic injection of opioid agonists: mu-agonist increases while kappa-agonist decreases stimulus thresholds for pain and reward.
Carr KD; Bak TH
Brain Res; 1988 Feb; 441(1-2):173-84. PubMed ID: 2833999
[TBL] [Abstract][Full Text] [Related]
26. The kappa opioid agonist U-50,488H antagonizes respiratory effects of mu opioid receptor agonists in conscious rats.
Dosaka-Akita K; Tortella FC; Holaday JW; Long JB
J Pharmacol Exp Ther; 1993 Feb; 264(2):631-7. PubMed ID: 8382278
[TBL] [Abstract][Full Text] [Related]
27. Antinociception produced by receptor selective opioids: modulation of spinal antinociceptive effects by supraspinal opioids.
Miaskowski C; Levine JD
Brain Res; 1992 Nov; 595(1):32-8. PubMed ID: 1334770
[TBL] [Abstract][Full Text] [Related]
28. Multiplicative interaction between intrathecally and intracerebroventricularly administered mu opioid agonists but limited interactions between delta and kappa agonists for antinociception in mice.
Roerig SC; Fujimoto JM
J Pharmacol Exp Ther; 1989 Jun; 249(3):762-8. PubMed ID: 2567350
[TBL] [Abstract][Full Text] [Related]
29. Kappa opioid partial agonist activity of the enkephalin-like pentapeptide BW942C based on urination and in vitro studies in humans and animals.
Vaupel DB; Cone EJ; Johnson RE; Su TP
J Pharmacol Exp Ther; 1990 Jan; 252(1):225-34. PubMed ID: 2153801
[TBL] [Abstract][Full Text] [Related]
30. Differential effects of specific opioid receptor agonists on rat pup isolation calls.
Carden SE; Barr GA; Hofer MA
Brain Res Dev Brain Res; 1991 Sep; 62(1):17-22. PubMed ID: 1662121
[TBL] [Abstract][Full Text] [Related]
31. Contribution of supraspinal mu- and delta-opioid receptors to antinociception in the rat.
Miaskowski C; Taiwo YO; Levine JD
Eur J Pharmacol; 1991 Dec; 205(3):247-52. PubMed ID: 1667910
[TBL] [Abstract][Full Text] [Related]
32. Body temperature response profiles for selective mu, delta and kappa opioid agonists in restrained and unrestrained rats.
Spencer RL; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1988 Jul; 246(1):92-101. PubMed ID: 2839673
[TBL] [Abstract][Full Text] [Related]
33. Selective kappa antagonist properties of nor-binaltorphimine in the rat MES seizure model.
Tortella FC; Echevarria E; Lipkowski AW; Takemori AE; Portoghese PS; Holaday JW
Life Sci; 1989; 44(10):661-5. PubMed ID: 2538689
[TBL] [Abstract][Full Text] [Related]
34. Differential regulation of the human kappa opioid receptor by agonists: etorphine and levorphanol reduced dynorphin A- and U50,488H-induced internalization and phosphorylation.
Li JG; Zhang F; Jin XL; Liu-Chen LY
J Pharmacol Exp Ther; 2003 May; 305(2):531-40. PubMed ID: 12606694
[TBL] [Abstract][Full Text] [Related]
35. Effects of microinjections of mu and kappa receptor agonists into the dorsal periaqueductal gray of rats submitted to the plus maze test.
Motta V; Penha K; Brandão ML
Psychopharmacology (Berl); 1995 Aug; 120(4):470-4. PubMed ID: 8539329
[TBL] [Abstract][Full Text] [Related]
36. Discriminative stimulus properties of U50,488 and morphine: effects of training dose on stimulus substitution patterns produced by mu and kappa opioid agonists.
Picker MJ; Doty P; Negus SS; Mattox SR; Dykstra LA
J Pharmacol Exp Ther; 1990 Jul; 254(1):13-22. PubMed ID: 2164087
[TBL] [Abstract][Full Text] [Related]
37. Opioid receptor subtypes involved in the central inhibition of urinary bladder motility.
Dray A; Metsch R
Eur J Pharmacol; 1984 Sep; 104(1-2):47-53. PubMed ID: 6094211
[TBL] [Abstract][Full Text] [Related]
38. Contrasting actions of intrathecal U50,488H, morphine, or [D-Pen2, D-Pen5] enkephalin or intravenous U50,488H on the visceromotor response to colorectal distension in the rat.
Harada Y; Nishioka K; Kitahata LM; Nakatani K; Collins JG
Anesthesiology; 1995 Aug; 83(2):336-43. PubMed ID: 7631956
[TBL] [Abstract][Full Text] [Related]
39. Comparative study of the effects of mu, delta and kappa opioid agonists on 3H-dopamine uptake in rat striatum and nucleus accumbens.
Das D; Rogers J; Michael-Titus AT
Neuropharmacology; 1994 Feb; 33(2):221-6. PubMed ID: 8035907
[TBL] [Abstract][Full Text] [Related]
40. Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies.
Devine DP; Leone P; Pocock D; Wise RA
J Pharmacol Exp Ther; 1993 Sep; 266(3):1236-46. PubMed ID: 7690399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
